ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2025
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS
Abstract readMulticenter Study
In one paragraph
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies.Translational lung cancer research · 2026Review
- CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma.Diagnostic pathology · 2026Article
- Hybrid Deep Learning-Machine Learning Fusion of Clinical, Radiomic and Deep Learning Features for Preoperative Differentiation of Solitary Pulmonary Mucinous Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Molecular characteristics, clonal relatedness and surgical outcomes of pulmonary mixed invasive mucinous and non-mucinous adenocarcinoma: a retrospective cohort study.Molecular biomedicine · 2026Article
- Multidimensional analysis of concurrent proximal bronchiolar adenoma and lung carcinoma.Journal of pathology and translational medicine · 2026Article
- FAAH initiates a positive feedback loop to promote lung adenocarcinoma progression through inhibition of ferroptosis.Cell death and differentiation · 2026Article
- Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer.The oncologist · 2026Article
- Article
- Clinical characteristics, prognosis, and nomograms for lung invasive mucinous adenocarcinoma with distant metastasis: a population-based study.Translational cancer research · 2026Article
- Inferring signaling pathway abnormalities from histopathological images via logic-constrained gene-pathway heterogeneous knowledge graph.npj biomedical innovations · 2026Article
- SMARCA4-deficient non-small cell lung cancer and immunotherapy resistance: mechanisms and novel strategies-a mini-review.Discover oncology · 2026Review
- Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report.Frontiers in oncology · 2026Article
- USP33 Promotes Lung Adenocarcinoma Brain Metastasis by Inhibiting the K48-Linked Ubiquitination and Degradation of S100A9 and Facilitating Vimentin Secretion.International journal of biological sciences · 2026Article
- Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma.Journal for immunotherapy of cancer · 2025Article
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nature reviews. Clinical oncology · 2025Review
- Prognostic Differences and Survival Predictive Models for Mucinous Versus Usual-Type Adenocarcinoma of the Uterine Cervix.Cancer medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
A Di FedericoLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
L HongDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
A ElkriefDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
R ThummalapalliDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
A J CooperMassachusetts General Hospital, Boston, USA.
B RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
S DigumarthyMassachusetts General Hospital, Boston, USA.
J V AlessiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
P GogiaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
F PecciLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
M MakaremLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
M M GandhiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
E GarboLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
A SainiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
A De GiglioDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
V FavoritoDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
S ScaleraClinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome.
L CiprianiClinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome.
D MarinelliDepartment of Experimental Medicine, Sapienza University, Rome, Italy.
D HaradonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
T NguyenLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
J HaradonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
E VolignyLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
V VazLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.
F GelsominoDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
F SperandiDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
B MelottiDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
M LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York.
J ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
D L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
J V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
M NishinoDepartment of Radiology, Brigham and Women's Hospital, Boston; Department of Imaging, Dana-Farber Cancer Institute, Boston.
J LindsayCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston.
S J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston.
K PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston.
L M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston.
X WangDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston.
B E JohnsonLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
P A JänneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
N RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York.
M Maugeri-SaccàClinical Trial Center, Biostatistics and Bioinformatics Division, IRCCS Regina Elena National Cancer Institute, Rome.
R S HeistMassachusetts General Hospital, Boston, USA.
A ArdizzoniDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna.
M M AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
K C ArbourDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
A J SchoenfeldDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York.
N I VokesDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
J LuoLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA. Electronic address: Jia_Luo@dfci.harvard.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MCTSA K12 Program at Harvard Medical SchoolK12TR004381 · NCATS · HARVARD MEDICAL SCHOOL · PI Karen K Miller · 2023 to 2026
$6.5MNCATS NIH HHS K12 TR004381NCI NIH HHS P30 CA008748
Abstract
backgroundApproximately 10% of lung adenocarcinomas (LUADs) have mucinous histology (LUAD PATIENTS AND
methodsPatients with LUAD from five institutions and The Cancer Genome Atlas Pan-Cancer Atlas classified as LUAD
resultsOf 4082 patients with LUAD, 9.9% had LUAD
conclusionsLUAD
Indexed as
Adenocarcinoma, MucinousAdenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Tumor MicroenvironmentAdultAgedAged, 80 and overBiomarkers, TumorFemaleGenomicsHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedBiomarkers, TumorImmune Checkpoint InhibitorsKRAS protein, humanProto-Oncogene Proteins p21(ras)genomicshistologyimmunotherapyKRAS inhibitorsmucinous lung adenocarcinomanon-small-cell lung cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.